Omega-3 compounds calm brain inflammation in early lab research
Immunoregulatory effects of DHEA and EPEA on activated microglia in vitro: The role of cannabinoid receptors.
AI Summary
This laboratory study investigated DHEA and EPEA, omega-3-derived ethanolamides that can interact with the endocannabinoid system, in activated microglia—immune cells in the brain that may contribute to central neuropathic pain. In cell cultures, both compounds reduced the expression of pro-inflammatory signals and increased anti-inflammatory mediators, including BMP7. The abstract does not report quantitative results, sample sizes, or clinical outcomes.
The study also found that substances released by activated microglia could stress neurons, while material from DHEA-treated microglia—and BMP7 alone—reduced this effect. The compounds acted through CB1 and CB2 receptor-associated pathways, suggesting that cannabinoid receptor signalling may help explain their anti-inflammatory effects. These findings support the therapeutic potential of DHEA and EPEA for central neuropathic pain, but they are based on in-vitro experiments and do not show that cannabis, THC, or CBD treats pain in people.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Pain research papers you might find interesting.
Interviews explore how adults with regular pain perceive cannabis use
An 18-month cohort found adverse outcomes were infrequent, but long-term risks…
Language models can extract documented cannabis use, but need validation
Explore More Research
Stay informed about the latest cannabis science.